The Scientific Advisory Board

The Scientific Advisory Board (SAB) of Enzypep consists of the following 5 people: Dr. Rinus Broxterman, Dr. Roland Callens, Dr. Paul ten Kortenaar, Prof. Dr. Dick Janssen and Dr. Rodney Lax.

Dr. Rinus Broxterman

Dr. Rinus Broxterman is an organic chemist by training (Ph.D. 1985 at Univ. of Groningen). He has worked a few years in the Flavor &Fragrance Industry (Quest Int) and joined DSM in 1989. He has held a number of different positions in R&D. This includes line/resource management , Project and Program Management and senior science positions. He is currently Corporate Scientist in DSM (department DSM Innovative Synthesis) in the Chemistry & Catalysis competence area, with a focus on Route Scouting & Assessment.

The red thread in his career is in identification and development of breakthrough routes for molecular products in a range of industry segments . The segments included agro chemicals, semi-synthetic antibiotics, the sweetener Aspartame, specialty & fine chemicals and especially pharmaceutical ingredients and intermediates (e.g enantiopure unnatural amino acids and small peptides) . He is co-author of > 200 papers, > 20 patent applications, and has given > 20 international lectures. He is a FRSC. Strategic contributions have been given, a.o., in technological assessment in a number of Due Diligences, formulation of the global DSM competence strategy in the area of Chemistry & Catalysis. He has supported in the spin-out Isobionics ( biotech manufacturing of Flavor & Fragrance intermediates). He has also supported in the spin-out Enzypep, where he now – from his position as Corporate Scientist of DSM – acts as part-time Strategy advisor.

Dr. Roland Callens

Dr. Roland Callens, a Belgian national, is peptide chemist by training (Ph.D. Univ. of Gent). At Solvay (Brussels) he set up the peptide division, Peptisyntha, and was the peptide specialist and R&D director for many years. He retired a few years ago and erected his own start-up company Ecolec.

Dr. Paul ten Kortenaar

Dr. Paul Ten Kortenaar is peptide chemist by training (Ph.D., Univ. of Nijmegen). He held several postdoc positions in The Netherlands and the USA before joining Diosynth (formerly part of the pharma division of AkzoNobel, later Merck) as head of the Peptide group. There his responsibilities increased over time to become R&D Director, responsible for all process support and R&D activities for peptides, alkaloids, steroids, heterocycles and classical biologics. He retired from this position within Merck a few years ago. Currently he has his own consultancy firm and is employed as senior advisor for a number of companies.

Prof. Dr. Dick Janssen

Prof. Dr. Dick Janssen (University of Groningen) is a chemist/biochemist by training and specialized in chemical microbiology and enzymology (Ph.D. Univ. of Nijmegen, 1982). After post-doc work and a KNAW fellowship to study protein engineering of dehalogenases, he was appointed full professor of Chemical Biotechnology at the Groningen Biomolecular Sciences and Biotechnology Institute (1993). His productive research group uses genomics and microbiological techniques for the discovery of new enzymes, and protein engineering including directed evolution to tailor enzymes for use in industrial applications. His team made important contributions on the discovery and application of dehalogenases and other hydrolases, on the engineering of synthetic properties of industrial enzymes, and recently explored the use of computational design for stability and selectivity improvement. He (co)authored over 250 peer-reviewed research papers and several patent applications and reviews

Dr. Rodney Lax

Dr. Rodney Lax trained as a biochemist in the UK and then worked for 15 years the field of steroid endocrinology at the University of Ulm and the University of Essen in Germany. He became Associate Professor of Physiological Chemistry at the University of Essen in 1985. From 1986 onwards, he focused his attention on peptide therapeutics, working at a number of small biotech and manufacturing organizations. Since 1998, he has worked for the PolyPeptide Group both in Europe and the USA. He is a recognized expert in the field of therapeutic peptides with an in-depth knowledge of taking therapeutic peptide candidates from NCE to commercial scale. Since January 2014, he has been working as a Business Development Consultant. Dr. Lax is a Director on the Board of the Peptide Therapeutics Foundation and also continues to act as a consultant to the PolyPeptide Group.